Community-Acquired Pneumonia Due to Pandemic A(H1N1)2009 Influenzavirus and Methicillin Resistant Staphylococcus aureus Co-Infection
Open Access
- 14 January 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (1), e8705
- https://doi.org/10.1371/journal.pone.0008705
Abstract
Bacterial pneumonia is a well described complication of influenza. In recent years, community-onset methicillin-resistant Staphylococcus aureus (cMRSA) infection has emerged as a contributor to morbidity and mortality in patients with influenza. Since the emergence and rapid dissemination of pandemic A(H1N1)2009 influenzavirus in April 2009, initial descriptions of the clinical features of patients hospitalized with pneumonia have contained few details of patients with bacterial co-infection. Patients with community–acquired pneumonia (CAP) caused by co-infection with pandemic A(H1N1)2009 influenzavirus and cMRSA were prospectively identified at two tertiary hospitals in one Australian city during July to September 2009, the period of intense influenza activity in our region. Detailed characterization of the cMRSA isolates was performed. 252 patients with pandemic A(H1N1)2009 influenzavirus infection were admitted at the two sites during the period of study. Three cases of CAP due to pandemic A(H1N1)2009/cMRSA co-infection were identified. The clinical features of these patients were typical of those with S. aureus co-infection or sequential infection following influenza. The 3 patients received appropriate empiric therapy for influenza, but inappropriate empiric therapy for cMRSA infection; all 3 survived. In addition, 2 fatal cases of CAP caused by pandemic A(H1N1)2009/cMRSA co-infection were identified on post–mortem examination. The cMRSA infections were caused by three different cMRSA clones, only one of which contained genes for Panton-Valentine Leukocidin (PVL). Clinicians managing patients with pandemic A(H1N1)2009 influenzavirus infection should be alert to the possibility of co-infection or sequential infection with virulent, antimicrobial-resistant bacterial pathogens such as cMRSA. PVL toxin is not necessary for the development of cMRSA pneumonia in the setting of pandemic A( H1N1) 2009 influenzavirus co-infection.Keywords
This publication has 33 references indexed in Scilit:
- Critical Care Services and 2009 H1N1 Influenza in Australia and New ZealandNew England Journal of Medicine, 2009
- Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009New England Journal of Medicine, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansNew England Journal of Medicine, 2009
- Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza PreparednessThe Journal of Infectious Diseases, 2008
- Deaths from Bacterial Pneumonia during 1918–19 Influenza PandemicEmerging Infectious Diseases, 2008
- Community-associated methicillin-resistant Staphylococcus aureus (MRSA) in AustraliaInternational Journal of Antimicrobial Agents, 2008
- Prevalence of Methicillin-Resistant Staphylococcus aureus Nasal Colonization among Taiwanese Children in 2005 and 2006Journal of Clinical Microbiology, 2007
- A 5′-nuclease real-time reverse transcriptase–polymerase chain reaction assay for the detection of a broad range of influenza A subtypes, including H5N1Diagnostic Microbiology and Infectious Disease, 2005
- Rapid detection of mecA and nuc genes in staphylococci by real-time multiplex polymerase chain reactionDiagnostic Microbiology and Infectious Disease, 2005
- Influenza-Associated Hospitalizations in the United StatesJama-Journal Of The American Medical Association, 2004